Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma
NCT ID: NCT03697655
Last Updated: 2019-01-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
274 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-12-10
Study Completion Date
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
NCT02477891
Multiple Myeloma
APPROVED_FOR_MARKETING
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565
Multiple Myeloma
COMPLETED
PHASE2
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
NCT03475628
Multiple Myeloma
UNKNOWN
PHASE2
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
NCT03710603
Multiple Myeloma
ACTIVE_NOT_RECRUITING
PHASE3
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
NCT02136134
Multiple Myeloma
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is composed of two phase 2 randomized multi-center substudies:
* PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical relapse
* PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD) reappearance
* PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical relapse
* PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD) reappearance
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Myeloma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
treatment arm and control (observation) arm
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PREDATOR-BR Cohort A
n=46, Daratumumab 20 MG/ML \[Darzalex\], 16 mg/kg body weight administered as an intravenous infusion
Group Type
EXPERIMENTAL
Daratumumab 20 MG/ML [Darzalex]
Intervention Type
DRUG
Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
PREDATOR-BR Cohort B
n=46, Control Group, Observation (no treatment)
Group Type
NO_INTERVENTION
No interventions assigned to this group
PREDATOR-MRD Cohort A
n=59, Daratumumab 20 MG/ML \[Darzalex\], 16 mg/kg body weight administered as an intravenous infusion
Group Type
EXPERIMENTAL
Daratumumab 20 MG/ML [Darzalex]
Intervention Type
DRUG
Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
PREDATOR-MRD Cohort B
n=59, Control Group, Observation (no treatment)
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daratumumab 20 MG/ML [Darzalex]
Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Darzalex
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of therapy; single or tandem autologous stem cell transplant is not considered a separate line of therapy and is not mandatory; and have achieved at least PR to last line of therapy, and who experience asymptomatic biochemical progression not meeting criteria for SPR.
2. Males and females ≥18 years of age.
3. Life expectancy of more than 3 months.
4. ECOG performance status of 0-2.
5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential.
9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
10. Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
11. Voluntary written informed consent.
1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of therapy; single or tandem autologous stem cell transplant is not considered a separate line of therapy and is not mandatory; and have achieved CR with negative MRD to the last line of therapy and who remain in CR MRD negative. The last response assessment confirming CR MRD negative status based on assessment of bone marrow sample using flow cytometry with sensitivity of at least 10-5 needs to be performed not earlier than 3 months before inclusion to the study.
2. Males and females ≥18 years of age.
3. Life expectancy of more than 3 months.
4. ECOG performance status of 0-2.
5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential
9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
10. Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
11. Voluntary written informed consent.
2. Males and females ≥18 years of age.
3. Life expectancy of more than 3 months.
4. ECOG performance status of 0-2.
5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential.
9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
10. Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
11. Voluntary written informed consent.
1. Patients with diagnosed symptomatic MM who have completed one or two prior lines of therapy; single or tandem autologous stem cell transplant is not considered a separate line of therapy and is not mandatory; and have achieved CR with negative MRD to the last line of therapy and who remain in CR MRD negative. The last response assessment confirming CR MRD negative status based on assessment of bone marrow sample using flow cytometry with sensitivity of at least 10-5 needs to be performed not earlier than 3 months before inclusion to the study.
2. Males and females ≥18 years of age.
3. Life expectancy of more than 3 months.
4. ECOG performance status of 0-2.
5. Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
6. ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
7. Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
8. Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential
9. FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
10. Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
11. Voluntary written informed consent.
Exclusion Criteria
1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG criteria.
2. Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by \< 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by \< 2 months.
3. Patients who have already started or received post-transplant maintenance or consolidation treatment.
4. Subject has received daratumumab or other anti-CD38 therapies previously.
5. Patients not able to tolerate daratumumab or required concomitant medication and procedures.
6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal.
7. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
9. Plasma cell leukemia.
10. Waldenström's macroglobulinemia.
11. CNS involvement.
12. Pregnant or lactating females.
13. Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
16. Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12-lead ECG during screening.
17. Patient who in investigator's opinion is unable to comply with the protocol requirements.
18. Uncontrolled hypertension or diabetes.
19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to enter the study.
20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer \< Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone.
22. Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
PREDATOR-MRD:
1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG criteria.
2. Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by \< 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by \< 2 months.
3. Patients who have already started or received post-transplant maintenance or consolidation treatment.
4. Subject has received daratumumab or other anti-CD38 therapies previously.
5. Patients not able to tolerate daratumumab or required concomitant medication and procedures.
6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal.
7. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
9. Plasma cell leukemia.
10. Waldenström's macroglobulinemia.
11. CNS involvement.
12. Pregnant or lactating females.
13. Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
16. Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12- lead ECG during screening.
17. Patient who in investigator's opinion is unable to comply with the protocol requirements.
18. Uncontrolled hypertension or diabetes.
19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to enter the study.
20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer \< Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone.
22. Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
2. Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by \< 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by \< 2 months.
3. Patients who have already started or received post-transplant maintenance or consolidation treatment.
4. Subject has received daratumumab or other anti-CD38 therapies previously.
5. Patients not able to tolerate daratumumab or required concomitant medication and procedures.
6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal.
7. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
9. Plasma cell leukemia.
10. Waldenström's macroglobulinemia.
11. CNS involvement.
12. Pregnant or lactating females.
13. Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
16. Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12-lead ECG during screening.
17. Patient who in investigator's opinion is unable to comply with the protocol requirements.
18. Uncontrolled hypertension or diabetes.
19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to enter the study.
20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer \< Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone.
22. Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
PREDATOR-MRD:
1. Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG criteria.
2. Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by \< 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by \< 2 months.
3. Patients who have already started or received post-transplant maintenance or consolidation treatment.
4. Subject has received daratumumab or other anti-CD38 therapies previously.
5. Patients not able to tolerate daratumumab or required concomitant medication and procedures.
6. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 \<50% of predicted normal.
7. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
8. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
9. Plasma cell leukemia.
10. Waldenström's macroglobulinemia.
11. CNS involvement.
12. Pregnant or lactating females.
13. Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
14. Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
15. Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
16. Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12- lead ECG during screening.
17. Patient who in investigator's opinion is unable to comply with the protocol requirements.
18. Uncontrolled hypertension or diabetes.
19. Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to enter the study.
20. Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
21. Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer \< Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone.
22. Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag Ltd.
INDUSTRY
Sponsor Role
collaborator
Bioscience, S.A.
INDUSTRY
Sponsor Role
collaborator
Polish Myeloma Consortium
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Krzysztof Jamroziak, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Polish Myeloma Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu; Oddział Hematologii i Transplantacji Szpiku
Poznan, Greater Poland Voivodeship, Poland
Site Status
RECRUITING
Instytut Hematologii i Transfuzjologii
Warsaw, Masovian Voivodeship, Poland
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Poland
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMC008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03768960
COMPLETED
PHASE4
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03652064
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT03746652
UNKNOWN
PHASE2
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT03236428
ACTIVE_NOT_RECRUITING
PHASE2
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT02076009
COMPLETED
PHASE3
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
NCT03450057
COMPLETED
PHASE2
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
NCT04656951
RECRUITING
PHASE2
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02951819
COMPLETED
PHASE2
Short Course Daratumumab in Patients With Multiple Myeloma
NCT03490344
COMPLETED
PHASE2
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
NCT02419118
COMPLETED
PHASE2/PHASE3
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667
ACTIVE_NOT_RECRUITING
PHASE2
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive
NCT03992170
UNKNOWN
PHASE2
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
NCT06353022
RECRUITING
PHASE2
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
NCT03143036
UNKNOWN
PHASE2
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105
COMPLETED
PHASE3
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
NCT03836014
ACTIVE_NOT_RECRUITING
PHASE3
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
NCT02252172
COMPLETED
PHASE3
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
NCT05243342
COMPLETED
PHASE1
Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
NCT03993912
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT04108195
ACTIVE_NOT_RECRUITING
PHASE1
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT03841565
WITHDRAWN
PHASE2
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
NCT05849610
ACTIVE_NOT_RECRUITING
PHASE2
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
NCT03215524
COMPLETED
PHASE2
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
NCT04352205
TERMINATED
PHASE2
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02116569
COMPLETED
PHASE1